TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07618325: A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Sponsor: MAXVAX Biotechnology Limited Liability Company · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07618325 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07618325 Rescue Dossier →